{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,5]],"date-time":"2026-05-05T04:21:12Z","timestamp":1777954872822,"version":"3.51.4"},"reference-count":32,"publisher":"American Society of Clinical Oncology (ASCO)","content-domain":{"domain":["ascopubs.org"],"crossmark-restriction":true},"short-container-title":["JCO Oncol Pract"],"abstract":"<jats:sec>\n                    <jats:title>PURPOSE<\/jats:title>\n                    <jats:p>Immunomodulatory agents (IMiDs) are critical in treating multiple myeloma (MM). We aimed to identify patterns of adherence to IMiD treatment, patient characteristics associated with adherence, and the corresponding survival among Medicare beneficiaries with newly diagnosed MM.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>METHODS<\/jats:title>\n                    <jats:p>Using group-based trajectory modeling, we identified distinct adherence groups among patients with MM in the SEER-Medicare database. Multinomial logistic regression models were used to identify factors associated with each adherence group. Cox proportional hazards regression models were sued to evaluate the impact of different adherence groups on survival.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>RESULTS<\/jats:title>\n                    <jats:p>We identified four distinct adherence groups among 4,452 patients with newly diagnosed MM between 2007 and 2019: (1) persistently-high (33.1%), (2) quick-decline-then-increase (17.5%), (3) moderate-decline (21.2%), and (4) quick-decline (28.2%). Factors related to poor-adherence groups included early treatment initiation years, patients with multiple comorbid conditions, hypercalcemia, renal failure, anemia, and bone disease and receiving a low-income subsidy. Patients age \u226585 years had higher odds of being in groups 3 and 4 than those age 66-69 years. Additionally, non-Hispanic Black patients were more likely to be in the quick-decline group than non-Hispanic White patients. Mortality was significantly associated with adherence. Patients in poor-adherence groups had a &gt;20% increased mortality risk, compared with the persistently-high group.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>CONCLUSION<\/jats:title>\n                    <jats:p>Old age, low-income subsidy recipients, and those with high comorbidity burden are less likely to be adherent to the IMiD treatment, and their survival outcomes are inferior compared with those in the high adherence group. Targeted intervention to assist adherence to their IMiD treatment may improve the survival for these populations with newly diagnosed MM.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1200\/op-25-00615","type":"journal-article","created":{"date-parts":[[2026,5,4]],"date-time":"2026-05-04T19:59:15Z","timestamp":1777924755000},"update-policy":"https:\/\/doi.org\/10.1200\/crossmark","source":"Crossref","is-referenced-by-count":0,"title":["Immunomodulatory Agent Adherence Trajectories and Survival Among Older Patients With Multiple Myeloma"],"prefix":"10.1200","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2169-4174","authenticated-orcid":true,"given":"Rong","family":"Wang","sequence":"first","affiliation":[{"name":"Department of Chronic Disease Epidemiology, Yale School of Public Health, New Haven, CT"},{"name":"Cancer Outcomes, Public Policy, and Effectiveness Research (COPPER) Center, Yale University, New Haven, CT"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1205-0369","authenticated-orcid":true,"given":"Mengmeng","family":"Ji","sequence":"additional","affiliation":[{"name":"Division of Public Health Sciences, Department of Surgery, Washington University School of Medicine in St. Louis, St. Louis, MO"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9038-077X","authenticated-orcid":true,"given":"Natalia","family":"Neparidze","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Section of Hematology, Yale School of Medicine, New Haven, CT"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9472-8032","authenticated-orcid":true,"given":"Xiaomei","family":"Ma","sequence":"additional","affiliation":[{"name":"Department of Chronic Disease Epidemiology, Yale School of Public Health, New Haven, CT"},{"name":"Cancer Outcomes, Public Policy, and Effectiveness Research (COPPER) Center, Yale University, New Haven, CT"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5872-9556","authenticated-orcid":true,"given":"Su-Hsin","family":"Chang","sequence":"additional","affiliation":[{"name":"Division of Public Health Sciences, Department of Surgery, Washington University School of Medicine in St. Louis, St. Louis, MO"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3294-5784","authenticated-orcid":true,"given":"Shi-Yi","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Chronic Disease Epidemiology, Yale School of Public Health, New Haven, CT"},{"name":"Cancer Outcomes, Public Policy, and Effectiveness Research (COPPER) Center, Yale University, New Haven, CT"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"233","published-online":{"date-parts":[[2026,5,4]]},"reference":[{"key":"e_1_3_8_2_2","unstructured":"Cancer Stat facts: Myeloma. https:\/\/seer.cancer.gov\/statfacts\/html\/mulmy.html"},{"key":"e_1_3_8_3_2","first-page":"140","article-title":"Revlimid (lenalidomide) now FDA approved as first-line therapy for patients with multiple myeloma","volume":"9","author":"Raedler LA","year":"2016","unstructured":"Raedler LA: Revlimid (lenalidomide) now FDA approved as first-line therapy for patients with multiple myeloma. Am Health Drug Benefits 9:140-143, 2016","journal-title":"Am Health Drug Benefits"},{"key":"e_1_3_8_4_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2020.11.014"},{"key":"e_1_3_8_5_2","unstructured":"National Comprehensive Cancer Network: NCCN Clinical Practice Guidelines in Oncology Multiple Myeloma 2025. April 11 2025. https:\/\/www.nccn.org"},{"key":"e_1_3_8_6_2","doi-asserted-by":"publisher","DOI":"10.37765\/ajmc.2023.89357"},{"key":"e_1_3_8_7_2","doi-asserted-by":"publisher","DOI":"10.18553\/jmcp.2020.26.2.186"},{"key":"e_1_3_8_8_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.clml.2019.09.618"},{"key":"e_1_3_8_9_2","doi-asserted-by":"publisher","DOI":"10.18553\/jmcp.2021.27.10.1457"},{"key":"e_1_3_8_10_2","doi-asserted-by":"publisher","DOI":"10.3111\/13696998.2015.1130710"},{"key":"e_1_3_8_11_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2018.36.15_suppl.e20031"},{"key":"e_1_3_8_12_2","first-page":"407","article-title":"Immunomodulator adherence in multiple myeloma patients with lower socioeconomic status: A retrospective study","volume":"32","author":"Ononogbu O","year":"2024","unstructured":"Ononogbu O, Akindele O, Yazdanfard S, et al: Immunomodulator adherence in multiple myeloma patients with lower socioeconomic status: A retrospective study. Support Care Cancer 32:407, 2024","journal-title":"Support Care Cancer"},{"key":"e_1_3_8_13_2","doi-asserted-by":"publisher","DOI":"10.1177\/1078155220980807"},{"key":"e_1_3_8_14_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2008-12-196543"},{"key":"e_1_3_8_15_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2009.26.3087"},{"key":"e_1_3_8_16_2","doi-asserted-by":"publisher","DOI":"10.1007\/s10549-012-2286-z"},{"key":"e_1_3_8_17_2","doi-asserted-by":"publisher","DOI":"10.3109\/0284186X.2013.844353"},{"key":"e_1_3_8_18_2","doi-asserted-by":"publisher","DOI":"10.1007\/s10552-013-0310-1"},{"key":"e_1_3_8_19_2","doi-asserted-by":"publisher","DOI":"10.1023\/A:1011240019516"},{"key":"e_1_3_8_20_2","article-title":"Development of an algorithm to distinguish smoldering versus symptomatic multiple myeloma in claims-based data sets","author":"Fiala MA","unstructured":"Fiala MA, Dukeman J, Tuchman SA, et al: Development of an algorithm to distinguish smoldering versus symptomatic multiple myeloma in claims-based data sets. JCO Clin Cancer Inform 10.1200\/CCI.17.00089","journal-title":"JCO Clin Cancer Inform"},{"key":"e_1_3_8_21_2","doi-asserted-by":"publisher","DOI":"10.1093\/gerona\/gly197"},{"key":"e_1_3_8_22_2","doi-asserted-by":"publisher","DOI":"10.1093\/gerona\/glx229"},{"key":"e_1_3_8_23_2","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/djs463"},{"key":"e_1_3_8_24_2","doi-asserted-by":"publisher","DOI":"10.1146\/annurev.clinpsy.121208.131413"},{"key":"e_1_3_8_25_2","doi-asserted-by":"publisher","DOI":"10.1089\/neu.2012.2578"},{"key":"e_1_3_8_26_2","doi-asserted-by":"publisher","DOI":"10.1177\/0049124101029003005"},{"key":"e_1_3_8_27_2","unstructured":"Medicare: Help with drug costs. https:\/\/www.medicare.gov\/basics\/costs\/help\/drug-costs"},{"key":"e_1_3_8_28_2","doi-asserted-by":"publisher","DOI":"10.1111\/jgs.12364"},{"key":"e_1_3_8_29_2","doi-asserted-by":"publisher","DOI":"10.1186\/s12913-014-0665-3"},{"key":"e_1_3_8_30_2","doi-asserted-by":"publisher","DOI":"10.1080\/13696998.2019.1580200"},{"key":"e_1_3_8_31_2","doi-asserted-by":"publisher","DOI":"10.1200\/OP.22.00008"},{"key":"e_1_3_8_32_2","article-title":"Adherence to pomalidomide in patients with multiple myeloma: A US-based claims study","volume":"36","author":"Gatwood J","year":"2018","unstructured":"Gatwood J, Dashputre A, Gatwood KS: Adherence to pomalidomide in patients with multiple myeloma: A US-based claims study. J Clin Oncol 36, 2018 (suppl 15; abstr e20008)","journal-title":"J Clin Oncol"},{"key":"e_1_3_8_33_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.clml.2018.01.006"}],"container-title":["JCO Oncology Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ascopubs.org\/doi\/pdfdirect\/10.1200\/OP-25-00615","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,4]],"date-time":"2026-05-04T19:59:17Z","timestamp":1777924757000},"score":1,"resource":{"primary":{"URL":"https:\/\/ascopubs.org\/doi\/10.1200\/OP-25-00615"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,4]]},"references-count":32,"alternative-id":["10.1200\/OP-25-00615"],"URL":"https:\/\/doi.org\/10.1200\/op-25-00615","relation":{},"ISSN":["2688-1527","2688-1535"],"issn-type":[{"value":"2688-1527","type":"print"},{"value":"2688-1535","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,4]]},"assertion":[{"value":"2025-06-19","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-02-02","order":1,"name":"revised","label":"Revised","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-04-03","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-05-04","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"OP-25-00615"}}